Literature DB >> 31104759

Reversal of rocuronium-induced neuromuscular block: is it time for sugammadex to replace neostigmine?

M Carron1, A De Cassai2, G Ieppariello2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 31104759      PMCID： PMC6676226          DOI： 10.1016/j.bja.2019.04.045

Source DB:  PubMed          Journal:  Br J Anaesth        ISSN： 0007-0912            Impact factor:   9.166


× No keyword cloud information.
  18 in total

1.  Effects of sugammadex on incidence of postoperative residual neuromuscular blockade: a randomized, controlled study.

Authors:  B Brueckmann; N Sasaki; P Grobara; M K Li; T Woo; J de Bie; M Maktabi; J Lee; J Kwo; R Pino; A S Sabouri; F McGovern; A K Staehr-Rye; M Eikermann
Journal:  Br J Anaesth       Date:  2015-05-02       Impact factor: 9.166

2.  Underlying reasons associated with hospital readmission following surgery in the United States.

Authors:  Ryan P Merkow; Mila H Ju; Jeanette W Chung; Bruce L Hall; Mark E Cohen; Mark V Williams; Thomas C Tsai; Clifford Y Ko; Karl Y Bilimoria
Journal:  JAMA       Date:  2015-02-03       Impact factor: 56.272

3.  Retrospective analysis of 30-day unplanned readmission after major abdominal surgery with reversal by sugammadex or neostigmine.

Authors:  Tak Kyu Oh; Ah-Young Oh; Jung-Hee Ryu; Bon-Wook Koo; In-Ae Song; Sun Woo Nam; Hee-Jung Jee
Journal:  Br J Anaesth       Date:  2019-01-02       Impact factor: 9.166

Review 4.  Efficacy and safety of sugammadex versus neostigmine in reversing neuromuscular blockade in adults.

Authors:  Ana-Marija Hristovska; Patricia Duch; Mikkel Allingstrup; Arash Afshari
Journal:  Cochrane Database Syst Rev       Date:  2017-08-14

5.  Clinical and financial impact of hospital readmissions after colorectal resection: predictors, outcomes, and costs.

Authors:  Rachelle N Damle; Nicole B Cherng; Julie M Flahive; Jennifer S Davids; Justin A Maykel; Paul R Sturrock; W Brian Sweeney; Karim Alavi
Journal:  Dis Colon Rectum       Date:  2014-12       Impact factor: 4.585

6.  Unplanned 30-day hospital readmission as a quality measure in gynecologic oncology.

Authors:  MaryAnn B Wilbur; Diana B Mannschreck; Ana M Angarita; Rayna K Matsuno; Edward J Tanner; Rebecca L Stone; Kimberly L Levinson; Sarah M Temkin; Martin A Makary; Curtis A Leung; Amy Deutschendorf; Peter J Pronovost; Amy Brown; Amanda N Fader
Journal:  Gynecol Oncol       Date:  2016-09-21       Impact factor: 5.482

7.  Reversal with sugammadex in the absence of monitoring did not preclude residual neuromuscular block.

Authors:  Yoshifumi Kotake; Ryoichi Ochiai; Takahiro Suzuki; Setsuro Ogawa; Shunichi Takagi; Makoto Ozaki; Itsuo Nakatsuka; Junzo Takeda
Journal:  Anesth Analg       Date:  2013-06-11       Impact factor: 5.108

8.  Association between intraoperative non-depolarising neuromuscular blocking agent dose and 30-day readmission after abdominal surgery.

Authors:  T Thevathasan; S L Shih; K C Safavi; D L Berger; S M Burns; S D Grabitz; R S Glidden; R D Zafonte; M Eikermann; J C Schneider
Journal:  Br J Anaesth       Date:  2017-10-01       Impact factor: 9.166

9.  A discrete event simulation model of clinical and operating room efficiency outcomes of sugammadex versus neostigmine for neuromuscular block reversal in Canada.

Authors:  Ralph P Insinga; Cédric Joyal; Alexandra Goyette; André Galarneau
Journal:  BMC Anesthesiol       Date:  2016-11-16       Impact factor: 2.217

10.  Sugammadex for reversal of neuromuscular blockade: a retrospective analysis of clinical outcomes and cost-effectiveness in a single center.

Authors:  Michele Carron; Fabio Baratto; Francesco Zarantonello; Carlo Ori
Journal:  Clinicoecon Outcomes Res       Date:  2016-02-18
View more
  1 in total

1.  Sugammadex in the management of myasthenic patients undergoing surgery: beyond expectations.

Authors:  Michele Carron; Alessandro De Cassai; Federico Linassi
Journal:  Ann Transl Med       Date:  2019-12
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.